Cell and Gene therapy have witnessed significant evolution and revolution over the past few decades. These innovative approaches hold immense promise for treating a wide range of diseases, including genetic disorders, cancer, and certain immune system disorders. Let's delve into their journey of evolution and revolution.
Evolution of Cell Therapy:
Cell therapy involves the use of living cells to restore or improve the functioning of damaged tissues or organs. Here are key milestones in the evolution of cell therapy:
The origins of cell therapy can be traced back to the successful use of bone marrow transplantation in the 1950s to treat blood disorders and certain cancers. This approach demonstrated the potential of transferring healthy cells to replace diseased or damaged cells.In the 1960s and 1970s, researchers identified hematopoietic stem cells (HSCs) as the key cells responsible for replenishing the blood and immune system. HSCT became a standard treatment for various blood cancers, such as leukemia and lymphoma.
Revolution of Cell Therapy:
The revolution in cell therapy began with the advent of genetic engineering and advances in molecular biology. Here are some pivotal moments:
Scientists began modifying cells genetically to enhance their therapeutic properties. In 1989, the first clinical trial involving genetically modified cells was conducted, marking a significant milestone. Genetically engineered T cells were used to treat a patient with advanced melanoma.
Chimeric Antigen Receptor T-cell (CAR-T) therapy, developed in the 1990s and early 2000s, revolutionized the field of cell therapy. CAR-T therapy involves modifying a patient's own T cells to express a synthetic receptor that recognizes and targets cancer cells. The FDA approved the first CAR-T cell therapy for pediatric acute lymphoblastic leukemia (ALL) in 2017, followed by approvals for other blood cancersInduced Pluripotent Stem Cells (iPSCs):
In 2006, scientists discovered a way to reprogram adult cells into a pluripotent state, creating induced pluripotent stem cells (iPSCs). iPSCs have the ability to differentiate into various cell types, similar to embryonic stem cells. This breakthrough opened up possibilities for personalized cell therapies and disease modeling.
Evolution of Gene Therapy:
Gene therapy aims to treat or cure diseases by introducing, modifying, or silencing genes within a patient's cells. Here are key milestones in the evolution of gene therapy:
In the 1990s, early clinical trials for gene therapy were conducted, primarily focusing on rare genetic disorders. These trials aimed to deliver functional copies of defective genes or introduce therapeutic genes into the patient's cells.
The development of safe and efficient viral vectors, such as adeno-associated viruses, in the late 1990s and early 2000s facilitated gene delivery into target cells. AAV-based gene therapies have shown promise in treating inherited retinal diseases and spinal muscular atrophy.
Revolution of Gene Therapy:
Gene therapy has undergone a revolution in recent years, driven by advances in gene editing technologies and improved delivery methods. Some notable developments include:
Gene therapy has achieved significant success in treating rare genetic diseases. The approval of Luxturna in 2017 for an inherited retinal disease marked the first FDA-approved gene therapy for an inherited genetic disorder. Several other gene therapies have since been approved for various rare diseases.In 2019, the FDA approved the first gene therapy for hemophilia, which uses a viral vector to deliver a functional copy of the gene responsible for blood clotting. Additionally, gene editing techniques like CRISPR-Cas9 hold promise for directly correcting genetic mutations in patients with hemophilia and other genetic disorders.
Gene therapy is expanding its applications beyond rare diseases. Clinical trials are underway for gene therapies targeting diseases like cancer, cardiovascular disorders, and HIV/AIDS. The potential of gene therapies to provide durable and curative treatments has sparked excitement and investment in the field.
In conclusion, the evolution and revolution of Cell and Gene therapy have transformed the landscape of modern medicine. These innovative approaches continue to advance, offering new hope for patients with previously untreatable diseases.
Overall, the evolution and revolution of Cell and Gene Therapy have been marked by scientific advancements, improved understanding of genetics and immunology, and successful clinical trials leading to transformative treatments for various diseases. As research and technology continue to progress, we can expect even more groundbreaking developments in this field.
Mantell Associates is a specialist Pharmaceutical and Life Sciences headhunting firm. To find out how we can assist with your business requirements, get in touch with Robin Mantell at +44 203 854 7723 or robin.mantell@mantellassociates.com
Sources:
Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351-360. URL: https://www.nature.com/articles/nature16009
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1709866
Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270. URL: https://www.nature.com/articles/nm.1880
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419. URL: https://science.sciencemag.org/content/302/5644/415